[New antitubercular agents are not where where we need them to be].
作者信息
Nau Jean-Yves
出版信息
Rev Med Suisse. 2015 Dec 16;11(499):2408-9.
PMID:26852561
Abstract
摘要
相似文献
1
[New antitubercular agents are not where where we need them to be].
Rev Med Suisse. 2015 Dec 16;11(499):2408-9.
2
India plans to expand access to new tuberculosis drug.
Lancet. 2017 Feb 18;389(10070):685. doi: 10.1016/S0140-6736(17)30394-X. Epub 2017 Feb 17.
3
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lancet Respir Med. 2017 Oct;5(10):772-774. doi: 10.1016/S2213-2600(17)30309-0. Epub 2017 Sep 5.
4
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Eur Respir J. 2018 Jul 4;52(1). doi: 10.1183/13993003.00934-2018. Print 2018 Jul.
5
Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
Lancet Infect Dis. 2019 May;19(5):470. doi: 10.1016/S1473-3099(19)30168-9.
6
Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
Eur Respir J. 2019 Jan 10;53(1). doi: 10.1183/13993003.01154-2018. Print 2019 Jan.
7
Compassionate and optimum use of new tuberculosis drugs.
Lancet Infect Dis. 2015 Oct;15(10):1131-1132. doi: 10.1016/S1473-3099(15)00296-0. Epub 2015 Sep 20.
8
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
N Engl J Med. 2015 Nov 12;373(20):1986-8. doi: 10.1056/NEJMc1505196.
9
Compassionate and optimum use of new tuberculosis drugs.
Lancet Infect Dis. 2015 Oct;15(10):1131. doi: 10.1016/S1473-3099(15)00294-7. Epub 2015 Sep 20.
10
Bedaquiline plus delamanid for XDR tuberculosis.
Lancet Infect Dis. 2016 Mar;16(3):294. doi: 10.1016/S1473-3099(16)00047-5.
Zotero 插件